Comparative Pharmacology
Head-to-head clinical analysis: NAPHCON FORTE versus TYZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPHCON FORTE versus TYZINE.
NAPHCON FORTE vs TYZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naphazoline acts as an agonist at alpha-adrenergic receptors in the vascular smooth muscle of the conjunctiva, causing vasoconstriction and reducing redness.
Imidazoline sympathomimetic amine that stimulates alpha-2 adrenergic receptors in the nasal vasculature, producing vasoconstriction and reducing nasal congestion.
1-2 drops of 0.1% solution in the affected eye(s) every 3-4 hours as needed.
Instill 1-2 drops of 0.1% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day.
None Documented
None Documented
Terminal elimination half-life is 9-11 hours; clinically, steady state is reached after 2-3 days of regular dosing.
Terminal elimination half-life is approximately 3-4 hours; clinically, this supports dosing every 8-12 hours.
Renal excretion of unchanged drug (65%) and metabolites (35%); less than 1% fecal.
Renal elimination of unchanged drug and metabolites accounts for approximately 50% of the dose; fecal elimination is minimal.
Category C
Category C
Ophthalmic Decongestant
Ophthalmic Decongestant